ADVT:

  Home   Astrology   Business   Indiafocus   Lifestyle   Movies   News   Parenting   Online Exam   Sports   Travel

HomeWorldEurope  
  
More News
Mamta defends hefty salaries
A rare love story!
Lok Sabha adjourned over...
Liberhan report in this...
China coal mine blast: 104...
China mine blast death toll 104
Govt to help obese woman in...
Red alert at Guj Kandla oil...
Three Mile Island Nuke plant...
Who should I deal with in Pak?:...
LeT's Google Earth link to...
Who should I deal with in Pak?:...
Four held for misbehaving with...
20 arrested in Orissa for...
No fear of ties suffering under...
Pak not serious on Mumbai...
Assam twin blast toll rises to...
Open gateways to dual use...
Dalai Lama doesn't want to...
Mumbaikars don't about security
Sikh groups seek justice for...


 
GlaxoSmithKline signs outsourcing deal with TCS
Monday, April 02, 2007 13:27 [IST]
IANS

London: GlaxoSmithKline (GSK), Britain's largest drug company, has signed an outsourcing deal with India's Tata Consulting Services to establish a drug development support facility in Mumbai.

A company statement said that under the terms of the deal, TCS will support GSK's global clinical research and development programme by providing outsourced data management and medical trial reporting services.

The arrangement will create nearly 100 new jobs on an existing site and reports say that the deal is understood to be worth more than £ 10 million.

GSK already has sizeable research operations in Mumbai and Bangalore and employs 2,400 people in India, where it controls 5.9 per cent of the pharmaceuticals market, The Times said.

Amber Salzman, senior vice-president of development operations at GSK, said in a statement that the company had picked TCS as a partner because of its strong record in knowledge process outsourcing and operational excellence.

Like many global companies GSK has been seeking to tap into India's pool of high-quality IT and scientific talent and is aiming to trim costs through outsourcing.

GSK is also involved in research collaboration with India's Ranbaxy Laboratories, to jointly develop drugs in areas such as urology, diabetes and asthma. Earlier this year, GSK announced that pre-tax profits rose 16 per cent in 2006 to £ 7.8 billion on the previous year, on turnover of £ 23.2 billion.


Add To

digg.com

del.icio.us

stumbleupon.com

My Yahoo

reditt.com

newsvine.com

fark.com
 Post Your Feedback   
Name
Email ID
Comments
 Other Features
News today
Screen Sever
Gallery
WallPaper
Print this page
Mail this page
Archives